Skip to main
MYO
MYO logo

Myomo (MYO) Stock Forecast & Price Target

Myomo (MYO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Myomo Inc. has demonstrated a robust growth trajectory in its reimbursement pipeline, which increased to 1,669 units, reflecting a positive trend from 1,389 units in the previous quarter. Additionally, with approximately 22% of projected revenue in 2024 coming from orthotics and prosthetics providers, the company is strategically redirecting its growth towards this burgeoning Medicare market. Furthermore, the recent positive ruling from the Centers for Medicare & Medicaid Services significantly expands the potential market for the MyoPro, positioning Myomo for enhanced financial performance and growth opportunities.

Bears say

Myomo Inc has significantly lowered its 2025 revenue guidance from $50 – 53 million to $40 – 42 million, indicating a notable decline in expected financial performance. Additionally, the company has reported a decrease in its insurance authorized backlog, which fell from 272 in Q4 to 208, suggesting a reduction in future sales potential. Despite potential growth opportunities, recent weaknesses in marketing effectiveness and lead quality have adversely impacted pipeline conversions, raising concerns about the company’s ability to meet its revised targets.

Myomo (MYO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myomo (MYO) Forecast

Analysts have given Myomo (MYO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Myomo (MYO) has a Strong Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myomo (MYO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.